Share Buyback Program - Smith & Nephew plc has initiated a USD $125 million share buyback program announced on February 22, 2022[4] - The company repurchased 493,119 ordinary shares on March 4, 2022, at a volume-weighted average price of £12.3887 per share[7] - Since February 23, 2022, the total shares purchased amount to 1,361,355 at a total cost of £17,267,533.81[7] - Following the recent purchases, the company holds 6,650,579 shares in Treasury[8] - The total issued share capital consists of 878,554,439 ordinary shares, excluding treasury shares[8]

Smith & Nephew plc (NYSE:SNN) Q4 2021 Earnings Conference Call February 22, 2022 3:30 AM ET Company Participants Roland Diggelmann - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Hassan Al-Wakeel - Barclays Tom Jones - Berenberg Veronika Dubajova - Goldman Sachs Lisa Clive - Bernstein David Adlington - JPMorgan Chris Gretler - Credit Suisse Operator Hello all and a warm welcome to the Smith & Nephew Fourth Quarter and Full Year 2021 Results Call. My nam ...

Smith Nephew Fourth Quarter and Full Year 2021 Results Forward looking statements and non-IFRS measures This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally ...

Smith & Nephew plc (NYSE:SNN) Q2 2021 Results Conference Call July 29, 2021 3:30 AM ET Company Participants Roland Diggelmann - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Patrick Wood - Bank of America Chris Gretler - Credit Suisse Tom Jones - Berenberg Kyle Rose - Canaccord Michael Jungling - Morgan Stanley Hassan Al-Wakeel - Barclays David Adlington - JPMorgan Kit Lee - Jefferies Veronika Dubajova - Goldman Sachs Operator Please note, certain state ...

Second Quarter and First Half 2021 Results Forward looking statements and non-IFRS measures This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 March 01, 2021 Commission File Number 001-14978 SMITH & NEPHEW plc (Registrant's name) Building 5, Croxley Park, Hatters Lane, Watford, Hertfordshire, WD18 8YE, England (Address of registrant's principal executive offices) [Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.] | Form ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F INFORMATION FOR SHAREHOLDERS (Mark One) ◻ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ◻ Other information XXX or Commission file number 1-14978 Board l ...

Fourth Quarter and Full Year 2020 Results Forward looking statements and non-IFRS measures This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to i ...

Smith & Nephew plc (NYSE:SNN) Q4 2020 Results Earnings Conference Call February 18, 2021 3:30 AM ET Company Participants Roland Diggelmann - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Lisa Clive - Bernstein Michael Jungling - Morgan Stanley Tom Jones - Berenberg Kyle Rose - Canaccord Kit Lee - Jefferies Operator Certain statements in this presentation are forward-looking statements. These statements are based on management’s current expectations and ...

Financial Data and Key Metrics Changes - Q3 revenue was $1.2 billion, a decline of 4.2% on an underlying basis and 3.7% on a reported basis [6][12] - The U.S. market returned to growth at 0.9% on an underlying basis, with revenue of $630 million [7][8] - Other Established Markets declined by 6.2% and Emerging Markets by 14.5% [7] Business Line Data and Key Metrics Changes - Orthopedics declined by 2.8% globally, with stronger performance in hips compared to knees [16] - Sports Medicine and ENT declined by 4.5% and Advanced Wound Management (AWM) by 6.1% [16] - Specific growth in Orthopedics was driven by emergency cases and the rollout of the OR3O Dual Mobility Hip System [17] Market Data and Key Metrics Changes - Established Markets showed mixed recovery, with Germany and France returning to growth, while the UK lagged [9][10] - In Asia Pacific, Australia and Japan saw procedure volumes recover to approximately 90% of normal levels [10] - Emerging Markets experienced varied performance, with China recovering strongly while other markets like India and South Africa remained under restrictions [11] Company Strategy and Development Direction - The company remains focused on long-term growth, continuing investments in R&D and M&A despite short-term challenges [14][24] - A conditional agreement to acquire Integra's orthopedics extremities business was announced, viewed as a high-growth category [24][25] - The company is enhancing its mid-term growth profile through product launches and digital technology capabilities [29][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the healthcare system's preparedness for COVID-19 impacts, although visibility remains limited [12][33] - The expectation is that the impact of COVID will continue into the first half of 2021, with full-year guidance withdrawn due to uncertainty [13] - The company aims to consistently outgrow its markets while improving trading profit margins [33] Other Important Information - The company has maintained its sales force without layoffs during the COVID-19 crisis, ensuring stability [93] - There is a focus on operational efficiency plans, particularly in manufacturing and supply chain [15] Q&A Session Summary Question: Differential between hip and knee growth - Management noted that both market factors and specific company factors contribute to the differential, with hips seeing more emergency cases [36] Question: Integra acquisition and expected returns - The acquisition is seen as a mix of technology and commercial capabilities, with a new shoulder system expected in 2022 [38] Question: Bond issue strategy - The company took advantage of low interest rates to diversify funding sources, moving away from reliance on bank loans [40] Question: Integra acquisition rationale - The acquisition complements the reconstruction business and provides access to the shoulder market, enhancing commercial capabilities [45] Question: U.S. Wound Care market trends - Management expects a good fourth quarter in Advanced Wound Management, driven by improvements in bioactives [47] Question: Wound Care market share and geographic mix - The company has a strong business in Europe, which has been more affected by COVID, but does not believe it has lost market share [51] Question: Margin outlook and foreign exchange impact - Transactional FX impact is expected to be around 50 basis points for both 2020 and 2021 [56] Question: Return to positive organic revenue growth - Management is optimistic about returning to growth that exceeds 2019 levels, depending on the management of COVID impacts [62] Question: Competitive dynamics in negative pressure market - The company believes it is well-positioned with strong products like PICO and is regaining market share in hospitals [68][71]